Cyclerion Therapeutics Inc
NASDAQ:CYCN
Intrinsic Value
Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for serious and orphan diseases, through th... [ Read More ]
There is not enough data to reliably calculate the intrinsic value of CYCN.
Cyclerion Therapeutics Inc's market capitalization is 8m USD.
CYCN stock price is 3.2182 USD.
CYCN.
CYCN. Open DCF Valuation
CYCN. Open Relative Valuation
CYCN has upside potential of 24% compared to the average analyst price target.
Open Wall St Estimates
CYCN's ROE (Return on Equity) has significantly increased in the last 3 years from -109% to -48%, and is approaching profitability.
CYCN's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from -114% to -306%, and is approaching profitability.
CYCN has negative Operating Income for the last twelve months.
CYCN has negative Net Income for the last twelve months.
CYCN's ROE (Return on Equity) for the past 12 months is negative and is equal to -48%.
CYCN's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -306%.
CYCN has negative Free Cash Flow for the last twelve months.
CYCN's short-term assets (8m USD) exceed its short-term liabilties (2m USD).
CYCN has negative three-year average ROE (Return on Equity): -116%. The company is not efficient at transforming stockholders' equity into net income.
CYCN has negative three-year average ROIC (Return on Invested Capital): -525%. The company is not efficient at using invested capital to generate operating income.
CYCN's long-term assets (13m USD) exceed its long-term liabilties (2m USD).
CYCN's D/E (Debt to Equity) is very low and is equal to 0.
CYCN's Altman Z-Score is very low and is equal to -27.82.
Fundamental Analysis
Cyclerion Therapeutics Inc
Balance Sheet Decomposition
Cyclerion Therapeutics Inc
| Current Assets | 8m |
| Cash & Short-Term Investments | 7.6m |
| Other Current Assets | 453k |
| Non-Current Assets | 5.4m |
| Long-Term Investments | 5.4m |
| Current Liabilities | 2.1m |
| Accounts Payable | 1.2m |
| Accrued Liabilities | 786k |
| Other Current Liabilities | 102k |
Earnings Waterfall
Cyclerion Therapeutics Inc
|
Revenue
|
0
USD
|
|
Operating Expenses
|
-9.6m
USD
|
|
Operating Income
|
-9.6m
USD
|
|
Other Expenses
|
4.4m
USD
|
|
Net Income
|
-5.3m
USD
|
Free Cash Flow Analysis
Cyclerion Therapeutics Inc
What is Free Cash Flow?
CYCN Profitability Score
Profitability Due Diligence
Cyclerion Therapeutics Inc's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
Score
Cyclerion Therapeutics Inc's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
CYCN Solvency Score
Solvency Due Diligence
Cyclerion Therapeutics Inc's solvency score is 60/100. The higher the solvency score, the more solvent the company is.
Score
Cyclerion Therapeutics Inc's solvency score is 60/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CYCN Price Targets Summary
Cyclerion Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for
CYCN
is 4 USD
.
Ownership
CYCN Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
CYCN Price
Cyclerion Therapeutics Inc
| Average Annual Return | -42.25% |
| Standard Deviation of Annual Returns | 43.86% |
| Max Drawdown | -99% |
| Market Capitalization | 8m USD |
| Shares Outstanding | 2 710 100 |
| Percentage of Shares Shorted | 1.11% |
Company Profile
Cyclerion Therapeutics Inc
Country
Industry
Market Cap
Dividend Yield
Description
Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for serious and orphan diseases, through the use of soluble guanylate cyclase (sGC) pharmacology. The company is headquartered in Boston, Massachusetts and currently employs 32 full-time employees. The company went IPO on 2019-03-18. The firm's lead asset, CY6463, is a central nervous system (CNS)-penetrant, soluble guanylate cyclase (sGC) stimulator that is in clinical development for Alzheimer's disease with vascular pathology (ADv), cognitive impairment associated with schizophrenia (CIAS), and mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes (MELAS). CY6463 is an orally administered CNS-penetrant sGC stimulator that is being developed as a symptomatic and disease-modifying therapy for serious CNS diseases. Its CNS asset, CY3018, is a differentiated CNS-penetrant sGC stimulator with CSF-to-plasma exposure relative to CY6463. CY3018 is focused on sGC stimulation for the treatment of disorders of the CNS. Its non-CNS assets include Praliciguat and Olinciguat. Praliciguat is an orally administered, once-daily systemic sGC stimulator. Olinciguat is an orally administered, once-daily, vascular sGC stimulator.
You don't have any saved screeners yet
